Home  >  Press Releases  >  Most Recent
Share

Press Releases

Press release year list 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006
December 11, 2009
Pfizer Animal Health is First to Develop, Manufacture and Receive USDA Approval NEW YORK, N.Y. - Swine producers have a new conditionally-licensed vaccine from Pfizer Animal Health to help protect their herds from the pandemic H1N1 (pH1N1) strain of Swine Influenza Virus (SIV).1  Pfizer Animal Health today announced that its Swine Influenza Vaccine, pH1N1 – Killed Virus, has been approved by the U.S. Department of Agriculture (USDA) for vaccination of healthy swine, including pregnant sows and gilts, three weeks of age or older against SIV subtype H1N1. Pfizer Animal Health became the first U.S. biologics manufacturer to receive a USDA conditional license for this new vaccine. Earlier this year, the USDA provided a master seed of the pH1N1 strain to multiple manufacturers in anticipation of potential transmission in swine herds. Producers today have not detected widespread transmission of the pH1N1 strain within swine herds. “This gives us hope that this pH1N1 strain can be managed by ...
October 16, 2009
Addition of Wyeth’s Fort Dodge products diversifies and enhances Pfizer Poultry Health’s growing poultry portfolio RALEIGH, N.C.-A new Pfizer Poultry Health was unveiled today as Pfizer’s global acquisition of Wyeth, and its subsidiary Wyeth / Fort Dodge Animal Health, was completed. The acquisition allows Pfizer Poultry Health, a unit of Pfizer Animal Health, to strengthen its position as a leader in the discovery, development and manufacturing of devices and vaccines for the global poultry industry. Fort Dodge brings an estimated 85 poultry products to those already available from Pfizer Poultry Health, resulting in a truly diversified product portfolio that is backed by unrivalled expertise and customer support. “This is a landmark occasion for Pfizer Poultry Health, which now includes even more best-in-class and innovative products,” said Joyce Lee, vice president, Pfizer Poultry Health. “The products, services and expertise we are gaining strengthen what is already an exceptional ...
September 9, 2009
-Inovotabs disinfectant tablets receive registration from the US EPA -Inovotabs were developed by Medentech® exclusively for use with the Embrex® Inovoject® System from Pfizer Poultry Health -Inovotabs facilitates optimal sanitation of the Inovoject System by effectively buffering filtered water at any pH level DURHAM, N.C.-Medentech, a solutions provider of clean water and cost effective disinfection solutions, recently announced that Inovotabs® brand disinfectant tablets received registration from the United States Environmental Protection Agency (EPA). Pfizer Poultry Health holds the exclusive sale and distribution rights for the product. Inovotabs are patented, highly effective sanitation tablets developed exclusively for use with the Embrex Inovoject System from Pfizer Poultry Health. The effervescent tablets allow for stable chlorine concentration and pH for up to 12 hours as compared to traditional hand-mixed sanitizer which typically must be prepared every four hours. When ...
July 23, 2009
Commercial hatchery trial proves viability of site of injection in ovo for optimal flock immunization RALEIGH, N.C.-How does site of injection affect the immunology of a bird when vaccinated in ovo? This question was addressed at the 2009 Poultry Science Association Meeting where Brett Hopkins, MS, DVM, Ph.D., DACPV, associate director for outcomes research with Pfizer Animal Health, presented data from a large scale commercial hatchery trial comparing the only two commercially available egg injection systems in the United States. When comparing the accuracy of delivery to the correct site of injection, Hopkins found that Pfizer’s Embrex® Inovoject® System exhibited significantly greater correct in ovo site of vaccine delivery (95.3 percent) as compared with in ovo delivery using Avitech’s ManualJectTM System (52.3 percent). In conjunction with Chris Williams, MS, Ph.D., director of poultry technical services Pfizer Poultry Health, Hopkins and Williams designed the trial to evaluate ...
January 28, 2009
Pfizer Poultry Health examines the theory behind the working mechanism of Bursaplex DURHAM, N.C.-Infectious Bursal Disease (IBD) is an ongoing threat to the poultry industry. Fortunately, controlling it is a challenge that can be met efficiently and effectively with Bursaplex, a revolutionary Antigen Antibody Complex (AAC) vaccine developed by the scientists from the Poultry Health Division of Pfizer Animal Health (PPH). For over a decade, Bursaplex has consistently aided poultry producers worldwide to raise healthy flocks. IBD is an acute and highly contagious viral infection of young chicks. It affects the bursa of Fabricius (BF), a highly specialized avian organ that assists birds in producing antibodies, much the same as bone marrow in mammals. When the immune system is compromised by IBD, birds become less capable of responding to vaccinations, and, at the same time, are more susceptible to all types of infectious diseases. While several IBDV vaccine options are commercially ...
January 28, 2009
DURHAM, N.C.-The U.S. poultry industry has the potential to achieve new standards of health and efficiency with the advent of the first-ever coccidiosis vaccine delivered via in ovo administration. The new Inovocox® vaccine from the Poultry Health Division of Pfizer Animal Health (PPH) will provide an innovative tool for the broiler industry to help control one of the global poultry industry’s most prevalent and costly diseases. The coccidiosis challenge Coccidiosis is an intestinal parasitic infection that is endemic to poultry production, and can cause considerable economic loss to the poultry industry in the form of lost growth and feed conversion efficiency, mortality, and medication and treatment costs. The economic impact of the disease on the world poultry industry is estimated to exceed US $3 billion annually. Novel vaccine, state-of-the-art delivery Pfizer Animal Health has invested greater than 10 years into the research and development of this advanced vaccine, which is ...
January 28, 2009
DURHAM, N.C.-An ever-growing world population, coupled with increasing feed costs and production pressures, will make demands on the global poultry industry greater than ever in years ahead. Poised to meet those demands is the Poultry Health Division of Pfizer Animal Health (PPH), a hybrid of engineering and poultry animal health technology and innovation that was born via the acquisition of Embrex, Inc. by Pfizer Animal Health in 2007. “The extensive poultry production knowledge; network of scientists and engineers that Embrex brought to the organization, coupled with Pfizer’s existing veterinary medicine research and development organization, is allowing our new organization to unlock the potential for developing and marketing new technologies to enhance global poultry production,” says Kirk Adams, Group Director, Global Marketing, New Business Marketing, and Strategic Planning. Future In Ovo Innovations The Embrex® Inovoject® System, a flagship product developed by Embrex, delivers ...
January 28, 2009
DURHAM, N.C.-The same technology used in broiler and broilerbreeder operations worldwide has another important application: manufacturing of human flu vaccine. The Poultry Health Division of Pfizer Animal Health (PPH) supplies global manufacturers of human flu vaccine with two widely used technologies: the Embrex® Inovoject® System, and the Embrex Inovoject System - Egg Remover®. “Poultry eggs currently are used as a growth medium for most human flu vaccines produced worldwide,” explains Jack Hebrank, Senior Principal Scientist for PPH. “The highly precise Inovoject System has been adapted for the purpose of inoculating the flu virus into eggs. Additionally, the Egg Remover system accurately candles and removes non-viable eggs between days 10 and 11 of incubation prior to inoculation.” The application of the Inovoject System to human vaccine production required a number of equipment modifications, as well as a verification process. The device was designed to meet sterility and quality ...